Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
12.58
+0.18 (+1.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Analyst Ratings for Arcutis Biotherapeutics
August 02, 2022
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
August 02, 2022
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.
Via
Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
July 29, 2022
Via
Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
July 29, 2022
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Biotech Stocks to Buy for Q3
July 18, 2022
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.
Via
InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
May 26, 2022
Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 25, 2022
Via
Benzinga
88 Biggest Movers From Yesterday
May 26, 2022
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
May 25, 2022
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) gained 178.3% to $0.3762 as the company announced it increased retail distribution across Canada with Loblaw Companies.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
December 23, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR). This additional capital...
Via
Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
December 23, 2021
The FDA has accepted Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) marketing application seeking approval for roflumilast cream for psoriasis in adults and...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
5 Stocks To Watch For December 23, 2021
December 23, 2021
Some of the stocks that may grab investor focus today are: Banner Corporation (NASDAQ: BANR) reported a buyback of 1.71 million shares, which is the equivalent of around 5% of...
Via
Benzinga
Is Now the Time to Bet on Arcutis Biotherapeutics?
September 18, 2021
Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?
Via
The Motley Fool
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study
July 01, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo. The study was ...
Via
Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
June 30, 2021
Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021
May 27, 2021
Upgrades Craig-Hallum upgraded the previous rating for NVIDIA Corp (NASDAQ:NVDA) from Hold to Buy. In the first quarter, NVIDIA showed an EPS of $3.66, compared to $1.80...
Via
Benzinga
55 Biggest Movers From Friday
May 03, 2021
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) jumped 45.5% to close at $49.80 on Friday after dropping around 22% on Thursday. Brooklyn ImmunoTherapeutics acquired...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 30, 2021
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock moved upwards by 30.17% to $1.42 during Friday's regular session. As of 12:31 EST, this security is trading at a volume of...
Via
Benzinga
38 Stocks Moving In Friday's Mid-Day Session
April 30, 2021
Gainers Image Sensing Systems, Inc. (NASDAQ: ISNS) rose 29.2% to $5.93 after the company announced it initiated a quarterly dividend of $0.12 per share, authorized a 220,000...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 30, 2021
Gainers Motus GI Hldgs (NASDAQ:MOTS) stock increased by 46.78% to $1.6 during Friday's pre-market session. The market value of their outstanding shares is at $74.7...
Via
Benzinga
Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation
April 23, 2021
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has announced the presentation of new safety and efficacy data of roflumilast foam to treat scalp and body...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.